Accessibility Tools

Dark Mode

Font Resize

Are you having difficulties using this site?

Contact Us

Professor OLUDOTUN PHILLIPS

Prof. O.A. Phillips
Phone
+9652636070
Public Email
oludotun.phillips@ku.edu.kw
Office Location
Health Sciences Center, College of Pharmacy, 2nd Floor, Room 2-81
College/ Center
College of Pharmacy
Professor

Professor Oludotun Adebayo Phillips is Professor of Pharmaceutical and Medicinal Chemistry at the Department of Pharmaceutical Chemistry, College of Pharmacy, Kuwait University.

Degrees and Certificates

Educational Background

Ph.D. (Pharmaceutical Chemistry / Organic Medicinal Chemistry, 1987) College of Pharmacy and Nutrition, University of Saskatchewan, Canada.

M.Sc. (Analytical Chemistry, 1982) Department of Chemistry, University of Ibadan.

B.Sc. (First Class Hons. 1980) Department of Chemistry, University of Ibadan, Nigeria.

Key Responsibilities

Lecturing, research activities and administrative duties on committees

Professional Experience

Full Professor, Faculty of Pharmacy Kuwait University, Kuwait (2009 to date). Associate Professor, Faculty of Pharmacy Kuwait University, Kuwait (1999-2009).

Chairman, Department of Pharmaceutical Chemistry, College of Pharmacy, Kuwait University (June 2003-March 2012) 

Manager (Group Leader), Antibacterial Drug Discovery Division, SynPhar Laboratories Inc. Canada (a subsidiary of Taiho Pharmaceuticals Inc., Japan) - 1998-1999.

Senior Research Scientist, Antibacterial Drug Discovery Division, SynPhar Laboratories Inc. Canada - 1994-1998.

Research Scientist, Antibacterial Drug Discovery Division, SynPhar Laboratories Inc. Canada - 1989-1994.

Postdoctoral Fellow, Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Canada - 1987-1989.

Teaching / Research Assistant, Faculty of Pharmacy and Nutrition, University of Saskatchewan, Canada - 1983-1987.

Teaching Assistant, Dept. of Chemistry, Faculty of Science, University of Ibadan, Nigeria - 1981-1983.

Lecturer, Dept. of Chemistry, The Polytechnic of Ibadan, Nigeria - 1980-1981.

Research Interests

Synthesis, structure elucidation and biological evaluation of novel small molecules containing the oxazolidine-2-one heterocyclic scaffold, as potential inhibitors of microbial growth, particularly of resistant Gram-positive pathogenic bacterial strains, inhibitors of human disease related enzymes, namely, 5-lipoxygenase, monoamine oxidases, and as anticonvulsant agents. 

Academic Subjects

Organic Chemistry, Pharmaceutical Chemistry courses, Advanced Pharmaceutical Chemistry, Techniques in Pharmaceutical & Pharmacological Research, Quality Control

Publications

  1. Phillips OA, Sharaf LH, Thomas V, Varghese T, Udo EE. (2023) Antibacterial Activity of N-Substituted-Amino Acid Triazolyl Oxazolidinones against Clinical Isolates of Linezolid-Resistant Gram-Positive Cocci and MDR Mycobacterium tuberculosis. J Drug Des Res 10(1): 1092.

  2. Al-Tannak NF, Phillips OA, Kamal HJ, Hemdan A (2022). Development and Validation of Stability-Indicating Assay Method for A Novel Oxazolidinone (PH-192) With Anticonvulsant Activity by Using UHPLC-QToF-MS. Molecules 2022, 27, 1090. https://doi.org/10.3390/molecules27031090

  3. Ezeamuzie CI, Rao MS, El-Hashim AZ, Phillips E, Phillips OA (2022). Anti-allergic, anti-asthmatic and anti-inflammatory effects of an oxazolidinone hydroxamic acid derivative (PH-251) – a novel dual inhibitor of 5-lipoxigenase and mast cell degranulation. International lmmunopharmacology International Immunopharmacology 105 (2022) 108558. https://doi.org/10.1016/j.intimp.2022.108558

  4. Qabazard B, Yousif M, Mousa A, Phillips OA (2021). GYY4137 attenuates functional impairment of corpus cavernosum and reduces fibrosis in rats with STZ-induced diabetes by inhibiting the TGF-β1/Smad/CTGF Pathway. Biomed Pharmacother 138, 111486. https://doi.org/10.1016/j.biopha.2021.111486

  5. Al-Hasawi NA, Phillips OA, Al-Awadhi F, Sharaf LH, Amine SA, Novotny N, (2020). Anti-proliferative effects of a series of glycinyl and alaninyl triazolyl-oxazolidinones on Kelly neuroblastoma cell line. Anticancer Research 40(9):5125-5140.

  6. Phillips OA, Bosso MA, Ezeamuzie CI (2020). Synthesis and structure-activity relationships of novel 5-(hydroxamic acid)methyl oxazolidinone derivatives as 5-Lipoxygenase inhibitors. J Enzym Inhib Med Chem 35:1, 1471-1482, http://dx.doi.org/10.1080/14756366.2020.1786082.

  7. Qabazard B, Masocha W, Khajah M, Phillips OA (2020). H2S donor GYY4137 ameliorates paclitaxel-induced neuropathic pain in mice. Biomed Pharmacother 127, 110210. https://doi.org/10.1016/j.biopha.2020.110210

  8. Nunhart P, Konkoľová E, Janovec L, Kašpárková J, Malina J, Brabec V, Matejová M, Miltáková B, Novotny L, Phillips OA, Udo EE, Kozurkova M (2020). Antimicrobial activity and DNA/HAS interaction of fluorinated 3,6,9-trisubstituted acridines. Chem. Pap.  https://doi.org/10.1007/s11696-020-01079-4

  9. Qaddoumi MG, Phillips OA, Kombian SB (2019). A novel oxazolidinone derivative PH192 demonstrates anticonvulsant activity in vivo in rats and mice. Eur. J. Pharm. Sci. 130:21-26. doi.org/10.1016/j.ejps.2019.01.011

  10. Qabazard B, Yousif MHM, Phillips OA (2019). Alleviation of impaired reactivity in the corpus cavernosum of STZ-diabetic rats by slow-release H2S donor GYY4137. Int J Impot Res 31, 111–118. https://doi.org/10.1038/s41443-018-0083-x

  11. Phillips OA, Udo EE, D’Souza RJ (2018). Structure-Antibacterial Activity Relationships of N-substituted-(D/L-alaninyl) 1H-1,2,3-Triazolylmethyl Oxazolidinones. Sci. Pharm. 86 (42) 1-20. doi:10.3390/scipharm86040042

  12. Al-Tannak NF, Phillips OA (2017). Antimycobacterial Activities of N-SubstitutedGlycinyl 1H-1,2,3-Triazolyl Oxazolidinones and Analytical Method Development and Validation for a Representative Compound. Sci. Pharm. 85(34) 1-16.

  13. Hedaya MA, Thomas V, Abdel-Hamid ME, Kehinde EO, Phillips OA (2017). Comparative Pharmacokinetic Study for Linezolid and Two Novel Antibacterial Oxazolidinone Derivatives in Rabbits: Can Differences in the Pharmacokinetic Properties Explain the Discrepancies between Their In Vivo and In Vitro Antibacterial Activities?
    Pharmaceutics 9(34) 1-15.

  14. Hedaya MA, Thomas V, Abdel-Hamid ME, Kehinde EO, Phillips OA (2017). A validated UPLC-MS/MS method for the analysis of linezolid and a novel oxazolidinone derivative (PH027) in plasma and its application to tissue distribution study in rabbits. J Liq Chromatogr B. 1040:89-96.

     

  15. Hedaya OM, Mathew PM, Hassan F, Phillips OA, Luqmani YA (2016). Anti-proliferative activity of a series of 5-(1H-1,2,3-triazolyl)methyl- and 5-acetamidomethyl-oxazolidinone derivatives. Mol Med Rep 13:3311-3318. 

  16. Phillips OA, D’Silva R, Bahta TO, Sharaf L, Udo EE, Benov L, DE Walters (2015). Synthesis and biological evaluation of novel 5-(hydroxamic acid)methyl oxazolidinone derivatives. Europ. J.Med. Chem. 106:120-131. 

  17. Phillips OA, Sharaf L, D’Silva R, Udo EE, Benov L (2015). Evaluation of the monoamine oxidases inhibitory activity of a small series of 5-(azole)methyl oxazolidinones. Europ. J. Pharm. Sci. 71:56-61. 

  18. Qaddoumi MG, Ananthalakshmi KVV, Phillips OA, Edafiogho IO, and Kombian SB (2014). Evaluation of anticonvulsant actions of dibromophenyl enaminones using in vitro and in vivo seizure models. PLOS ONE 9(6): e99770. doi:10.1371/journal.pone.0099770. 
  19. Edafiogho IO, Qaddoumi MG, Ananthalakshmi KVV,  Phillips OA and  Kombian SB (2014). Synthesis, neuronal activity and mechanisms of action of halogenated enaminones. Eur. J. Med. Chem. 76:20-30.

  20. Phillips OA, Udo EE, Abdel-Hamid ME and Varghese R. (2013). Synthesis and antibacterial activities of N-substituted-glycinyl 1H-1,2,3-triazolyl oxazolidinones. Europ. J. Med. Chem. 66:246-257. 

     

  21. Kombian SB and Phillips OA (2013). Novel actions of oxazolidinones: in vitro screening of a triazolyloxazolidinone for anticonvulsant activity. Med. Princ. Pract. 22:340-345; (DOI: 10.1159/000346005).

  22. Phillips OA; Udo EE; Abdel-Hamid ME and Varghese R. (2012). Effects of Varied Substituents on the Antibacterial Activity of Triazolyl Oxazolidinones. Arch. Pharm. Chem. Life Sci. 345, 790-803.

  23. Abdel-Hamid ME; Sharaf LH; Phillips OA; Kehinde EO and Babu A. (2012). A Rapid liquid Chromatography-Tandem Mass Spectrometry Method for the Determination of Ciprofloxacin in Rabbits Serum Following Intra-gastric Dosing: Application to Pharmacokinetics Study. Research Journal of Pharmacy and Technology 5(5): 624-631.

  24. Phillips OA; Udo EE; and Varghese R. (2012). Anti-mycobacterial activities of novel 5-(1H-1,2,3-triazolyl)methyl oxazolidinones. Tuberculosis Research and Treatment, vol 2012, Article ID 289136, 1-7 pages, doi:10.1155/2012/289136. 

  25. Abdel-Hamid ME; Sharaf LH; Phillips OA and Kehinde EO (2011). A Validated LC-MS/MS Method for the Determination of Tamsulosin Hydrochloride in Six Brands; Applications to Content Uniformity and Dissolution Studies. Research Journal of Pharmacy and Technology 4(12):1885-1890.

  26. Kombian SB; and Phillips OA. (2011). Investigations on the effects of linezolid and novel oxazolidinones on central nervous system neurons in vitro. Neurosci. 180:53-63.

  27. Pintér G; Bereczki I; Rőth E; Sipos A; Varghese R; Udo EE; Ostorházi E; Rozgonyi F; Phillips OA; Pál Herczegh P. (2011). The effect of systematic structural modifications on the antibacterial activity of novel oxazolidinones. Med. Chem. 7:45-55.

  28. Phillips OA; Sharaf LH; Abdel-Hamid ME and Varghese R. (2011). Assessment of the stability of novel antibacterial triazolyl-oxazolidinones using a stability-indicating high performance liquid chromatography method. Med. Princ. Pract. 20:51-59.

  29. Phillips OA; Udo EE; Abdel-Hamid ME and Varghese R. (2009). Synthesis and antibacterial activity of novel 5-(4-methyl-1H-1,2,3-triazolyl)methyl oxazolidinones. Europ. J. Med. Chem. 44:3217-3227.

  30. Edafiogho EE; Phillips OA; Udo EE; Samuel S and Rethish B. (2009). Synthesis, antibacterial and anticonvulsant evaluations of some cyclic enaminones. Europ. J. Med. Chem. 44:967-975.

  31. Phillips OA and Abdel-Hamid ME. (2008). Determination of novel antibacterial triazolylmethyl oxazolidinones concentrations in human plasma by APCI-LC-MS: Application to stability study. J. Pharm Pharmceut Sci 11(2):22s-31s.

  32. Phillips OA; Udo EE and Samuel S. (2008). Synthesis and structure-antibacterial activity of triazolyl oxazolidinones containing long chain acyl moiety. Europ. J. Med. Chem. 43:1095-1104.

  33. Phillips OA; Udo EE; Ali AAM; and Samuel S. (2007). Structure-antibacterial activity of arylcarbonyl- and arylsulfonyl-piperazine 5-triazolylmethyl oxazolidinones. Europ J Med Chem 42:214-225. 

  34. Al-Lanqawi Y, Capps P, Abdel-Hamid M, Abdulmalek K, Phillips D, Matar K, Sharma P, Thusu A (2007) Therapeutic drug monitoring of gentamicin: evaluation of five nomograms for initial dosing at Al-Amiri Hospital in Kuwait. Med Princ Pract. 16: 348 – 354.

  35. Novotny L; Phillips OA; Rauko P; Miadokova E. (2006). Antileukemic activity of sulfanilamide conjugates of arabinosylcytosine. Exp Oncol 28:293-298.

  36. Phillips OA; Mathew K.T.; Oriowo MA. (2006). Antihypertensive and vasodilator effects of methanolic and aqueous extracts of Tribulus terrestris in rats. J Ethnopharmacol 104:351-355.

  37. Phillips OA; Udo EE; Ali AAM; and Samuel S. (2005). Synthesis and antibacterial activity of new N-linked 5-triazolylmethyl oxazolidinones. Bioorg Med Chem 13:4113-4123.

  38. Phillips OA; Reddy AVN; Setti EL; Spevak P; Czajkowski DP; Atwal H; Salama S; Micetich RG; Maiti SN. (2005). Synthesis and biological evaluation of penam sulfones as inhibitors of β-lactamases. Bioorg Med Chem 13(8): 2847-2858. [Erratum in Bioorg Med Chem 13:6276]. 

  39. Al-Sweih N; Mokaddas E; Jamal W; Phillips OA; Rotimi VO. (2005). In vitro activity of linezolid and other antibiotics against Gram-positive bacteria from the major teaching hospitals in Kuwait. J Chemother 17:607-613. 

  40. Abdel-Hamid ME; Phillips OA; (2003). LC-MS/MS determination of Synercid® injections. J. Pharm. Biomed. Anal. 32:1167-1174. 

  41. Phillips OA; Rotimi VO; Jamal WY; Shahin M; Verghese TL. (2003). Comparative in vitro activity of PH-027 versus linezolid and other anti-anaerobic antimicrobials against clinical isolates of Clostridiumdifficile and other anaerobic bacteria. J Chemother 15:113-117. 

  42. Abdel-Hamid ME; Phillips OA. (2003). LC-MS/MS determination of carbamazepine, pindolol and theophylline in human serum. J Liq Chromatogr Related Technolog 26:1937-1957.

  43. Udo EE; AL-Sweih N; Phillips OA; Chugh TD. (2003). Species prevalence and antibacterial resistance of enterococci isolated in Kuwait hospitals. J Med Microbiol 52:163-168. 

  44. Phillips OA; Udo EE; Ali AAM; Al-Hassawi N. (2003). Synthesis and antibacterial activity of 5-substituted oxazolidinones. Bioorg Med Chem 11:35-41. 

  45. Edafiogho EE; Phillips OA; Abdel-Hamid M; Ali AAM; Matowe WC; El-Hashim A; Kombian SB. (2002). Ultraviolet spectroscopy of anticonvulsant enaminones. Bioorg Med Chem 10: 593-597. 

  46. Phillips OA; Udo EE; Ali AAM; Mokaddas EM. (2001). Comparative antimicrobial activities of linezolid and vancomycin against Gram-positive clinical isolates from hospitals in Kuwait. Med Principles Pract 10: 177-181.   

  47. Phillips OA; Abdel-Hamid M; Al-Hassawi N. (2001). Determination of linezolid in human plasma by LC-MS-MS. The Analyst 126: 609-614. 

  48. Nishida K; Kunugita C; Uji T; Higashitani F; Hyodo A; Unemi N; Maiti SN; Phillips OA; Spevak P; Atchison K; Salama SM; Atwal H; Micetich RG. (1999). In vitro and in vivo activity of Syn2190, a novel β-lactamase inhibitor. Antimicrob Agents Chemother 43: 1895-1900.

  49. Phillips OA; Murthy KSK; Fiakpui CY; Knaus EE. (1999). Synthesis of 5-phenyl-10-methyl-7H-pyrimido[4,5-f][1,2,4]triazolo[4,3-a][1,4]diazepine and its evaluation as an anticonvulsant agent. Can J Chem 77:  216-222. 

  50. Fiakpui CY; Phillips OA; Murthy KSK; Knaus EE. (1999). Synthesis and anticonvulsant activities of 5-(2-chlorophenyl)-7H-pyrido[4,3-f][1,2,4]triazolo[4,3-a][1,4]diazepines. J Heterocycl Chem 1999; 36: 337-380. 

  51. Phillips OA; Czajkowski DP; Atchison K; Micetich RG; Maiti SN; Kunugita C; Hyodo A. (1998). Studies on monobactams I. Synthesis and b-lactamase inhibitory activity of 4-substituted-3-[(N-methyl-1,2,3-triazol-4-yl)methylene]-2-azetidinone-1-sulfonate. Chem Heterocyl Compds 11: 1536-1547. 

  52. Phillips OA; Setti EL; Reddy AVN; Micetich RG; Kunugita C; Hyodo A; Maiti SN. (1998). Studies on Monobactams II.  Synthesis and b-lactamase inhibitory activity of 4a-methyl-3-[(thiophen-2-yl)methylene]-2-azetidinone-1-sulfonate. Chem Heterocyl Compds 11: 1548-1552. 

  53. Phillips OA; Czajkowski D; Spevak P; Singh MP; Hanehara-Kunugita C; Hyodo A; Micetich; RG; Maiti SN; (1997). SYN-1012: A new b-lactamase inhibitor of penem skeleton. J Antibiotics 50: 350-356. 

  54. Reddy AVN; Setti EL; Phillips OA; Czajkowski DP; Atwal H; Atchison K; Micetich RG; Maiti SN; Kunugita C; Hyodo A. (1997). Studies on penam sulfones II: Synthesis and b-lactamase inhibitory activity of 2b-carboxamide penicillanic acid sulfones. J Antibiotics 50: 276-278. 

  55. Czajkowski DP; Reddy AVN; Setti EL; Phillips OA; Micetich RG; Kunugita C; Maiti SN. (1997). Studies on penam sulfones III. Synthesis and b-lactamase inhibitory activity of sodium (6R)-6-(a-hydroxybenzyl)-2b-methoxyiminomethyl-2a-methylpenam-3a-carboxylate 1,1-dioxide and sodium 2b-acyl-2a-methylpenam-3a-carboxylate 1,1-dioxide. Bioorg Med Chem Lett 7: 11-14. 

  56. Setti EL; Reddy AVN; Phillips OA; Czajkowski DP; Atchison K; Atwal H; Micetich RG; Maiti SN; Kunugita C; Hyodo A. (1997). Studies on penam sulfones I. Synthesis and b-lactamase inhibitory activity of 2b-alkoxycarbonyl penicillanic acid sulfones. J. Antibiotics 49: 944-946. 

  57. Eby P; Cummings MD; Phillips OA; Czajkowski DP; Singh MP; Spevak P; Micetich RG; Maiti SN. (1996). b-Lactamase inhibitors: Synthesis and in vitro evaluation of 6-[(1-substituted-1,2,3-triazol-4-yl)methylene]penicillanic acid sulfones. Heterocycles 42: 653-668. 

  58. Setti EL; Phillips OA; Reddy AVN; Kunugita C; Hyodo A; Micetich RG; Maiti SN. (1996). Synthesis and biological evaluation of sodium 2-b-[(2,5-dihydro-6-hydroxy-2-methyl-5-oxo-1,2,4-triazin-3-yl)sulfonylmethyl]-2a-methylpenam-3a-carboxylate-1,1-dioxide. Heterocycles 42: 645-651. 

  59. Setti EL; Fiakpui C; Phillips OA; Czajkowski DP; Atchison K; Micetich RG; Maiti SN. (1995). Chemical modification of tazobactam: Synthesis of 2b-[(4-substituted)-1,2,3-triazol-1-yl]methylpenicillanic acid sulfone derivatives. J. Antibiotics 48: 1320-1329. 

  60. Phillips OA; Eby P; Maiti SN. (1995). Conversion of cis-aldehyde to trans-aldehyde using thioacetamide and thiourea. Synth Communic 25: 87-93. 

  61. Im C; Maiti SN; Micetich RG; Daneshtalab M; Atchison K; Phillips OA; Kunugita C. (1994). Synthesis and b-lactamase inhibitory activity of 6-[(1-heteroarylthio-ethyl-1,2,3-triazol-4-yl)methylene]penam sulfones. J. Antibiotics 47: 1030-1040. 

  62. Cummings MD; Czajkowski DP; Brunstein J; Reddy AVN; Phillips OA; Fiakpui C; Spevak P; Micetich RG; Maiti SN. (1994). 2a-Alkoxymethyl cephalosporins: reactions of exo-2-methylene cephalosporin sulfones with alcohols.  Collect Czech Chem Commun 59: 2282-2292. 

  63. Phillips OA; Knaus EE. (1993). Synthesis of 6,7,8,9-tetrahydro-5H-pyrimido-[4,5-b]-[1,4]diazepine-6,8-diones. J Heterocycl Chem 30: 283-285. 

  64. Fiakpui CY; Phillips OA; Murthy KK; Knaus EE. (1993). Synthesis and anticonvulsant activity of 1,3-dihydro-5-phenyl-2H-pyrido[3,4-e]-1,4-diazepin-2-ones. Drug Design and Discovery 10: 45-55. 

  65. Dimmock JR; Jonnalagadda SS; Phillips OA; Erciyas E; Shyam K; Semple HA. (1992). Anticonvulsant properties of some Mannich bases of conjugated arylidene ketones. J. Pharm Sci 81: 436-440. 

  66. Phillips OA; Knaus EE. (1991). Synthesis and anticonvulsant activity of 3-(3'-trifluoro-methylphenoxy)pyridines and dihydropyridines. Drug Design and Delivery 7: 279-286. 

  67. Czajkowski D; Phillips OA; Reddy AVN; Spevak P; Lix B; Micetich RG; Maiti SN. (1991). Preparation of 7-spiroepoxy and 7,7-disubstituted cephalosporanate-1,1-dioxide from 7-diazocephalosporanate-1,1-dioxide: Reactions of 7-diazocephalosporanate-1,1-dioxide with aldehydes. Collect Czech Chem Commun 56: 2352-2361. 

  68. Rousseaux CG; Townsend HG; Phillips OA; Dimmock JR. (1990) Toxicologic studies on a novel antineoplastic bis-Mannich base derived from a conjugated styryl ketone.  Fundament Applied Toxicology 14: 318-326. 

  69. Phillips OA; Nelson LA; Knaus EE; Allen TM; Fathi-Afshar R. (1989). Synthesis and cytotoxic activity of pyridylthio, pyridylsulfinyl, pyridylsulfonyl methyl acrylates. Drug Design and Delivery 4: 121-127. 

  70. Mutus B; Wagner JD; Talpas CJ; Dimmock JR; Phillips OA; Reid RS. (1989). 1-p-Chlorophenyl-4,4-dimethyl-5-diethylamino-1-penten-3-one hydrobromide, a sulfhydryl-specific compound which reacts irreversibly with protein-thiols but reversibly with small molecular weight thiols. Anal Biochem 177: 237-243.

  71. Dimmock JR; Phillips OA; Wonko SL; Hickie RA; Teur RG; Ambrose SJ; Reid RS; Mutus B; Talpas CJ. (1989). Evaluation of some Mannich bases of conjugated styryl ketones and related compounds versus the WiDr colon cancer in vitro. Europ J Med Chem 24: 217-229. 

  72. Clavijo RE; Mutus B; Aroca R; Dimmock JR; Phillips OA. (1988). SERS of a,b-unsaturated ketones on colloidal silver. J. Raman Spectroscop 19: 541-546. 

  73. Dimmock JR; Brenner JM; Phillips OA. (1987). Evaluation of some benzene- sulphonylhydrazones of aryl aldehydes and ketones as antineoplastic agents. Die Pharmazie 42: 376-378. 

  74. Dimmock JR; Hamon NW; Waslen TA; Patil SA; Phillips OA; Jonnalagadda SS; Hancock DS. (1986). Effect of some Mannich bases derived from aryl a,b-unsaturated ketones on respiration in mouse liver mitochondria.  Die Pharmazie 41: 441-442.

 

Review articles: 

  1. Phillips OA; Al-Soraj M (2016) Proceedings of the 5th Kuwait International Pharmacy Conference, February 1-3, 2015. Medical Principles and Practice 25(2):1-2.

  2. Phillips OA; Sharaf LH. (2016). Oxazolidinone antimicrobials: a patent review (2012-2015). Expert Opin Ther Patents 25(5):591-605. 

  3. Phillips OA; Sharaf LH. (2009). 5-Hydroxymethyl-oxazolidinones Actelion Pharmaceutucals: WO2008062379. Expert Opin Ther Patents 19(4):1-12. 

  4. Phillips OA; Sharaf LH. (2007). Pleuromutilin antibacterial agents patent review 2001 to 2006. Expert Opin Ther Patents 17(4):429-435. 

  5. Phillips OA. (2006). b-Lactamase inhibitors: a survey of the patent literature 2000 to 2004. Expert Opin Ther Patents 16(3):319-331. 

  6. Phillips, OA. (2005). Antibacterial agents: Patent highlights January 2005 to June 2005. Curr Opin Invest Drugs 6(8):768-780.

  7. Phillips OA. (2004). Antibacterial agents: Patent highlights January to June 2004. Curr Opin Invest Drugs 5(8):799-808. 

  8. Phillips OA. (2003). Antibacterial agents: Patent highlights January to June 2003. Curr Opin Invest Drugs 4(8):926-936. 

  9. Phillips OA. (2003). Antibacterial agents: Patent highlights July to December 2002. Curr Opin Invest Drugs 4(2):117-127. 

  10. Phillips OA. Matowe W.C. (2002). Antibacterial agents: Patent highlights January 2002 to June 2002. Curr Opin Invest Drugs 3 (12):1701-1711.

  11. Phillips OA; Matowe W.C. (2001). Antibacterial agents (oxazolidinones, quinolones, macrolides and new agents): Patent highlights June to December 2000. Curr Opin Invest Drugs 2(6): 745-751.

  12. Maiti SN; Phillips OA. (1999). b-Lactamase Inhibitors and b-lactam antibiotics: Patent highlights June 1998 to November 1998. Curr Opin Antiinfect Invest Drugs 1(1): 40-44. 

  13. Maiti SN; Phillips OA; Micetich RG; Livermore DM. (1998). b-Lactamase inhibitors: agents to overcome bacterial resistance. Curr Med Chem 5(6):  441-456.

 

Patents: 

  1. Ezeamuzie CI; Phillips OA. Oxazolidinone hydroxamic acid derivatives. US Patent  No. US 11,608,320 B2, March 21, 2023. 

  2. Maiti SN; Reddy AVN; Sameeh S; Czajkowski DP; Phillips OA; Heip L. Monobactam derivatives as beta-Lactamase inhibitors. US Application Serial Number 60/983.394 filed October 29, 2007.

  3. Maiti SN; Phillips OA; Reddy AVN; Setti EL; Micetich RG; Kunugita C; Higashitani F; Hyodo A. Penam sulfones as b-Lactamase inhibitors. European Patent, EP, US 5994340; January 22, 2003. 

  4. Maiti SN; Phillips OA; Setti EL; Reddy AVN; Micetich RG; Higashitani F; Kunugita C; Nishida K; Uji T; Azetidinone derivatives as b-lactamase inhibitors. United States Patent, US 5994340; November 30 1999. 

  5. Maiti SN; Setti EL; Phillips OA; Reddy AVN; Micetich RG; Singh R; Higashitani F; Kunugita C; Nishida K; Uji T. 2-Oxo-1-azetidine sulfonic acid derivatives as potent b-lactamase inhibitors. United States. Patent, US 5888998; March 30 1999. 

  6. Maiti SN; Setti EL; Phillips OA; Reddy AVN; Micetich RG; Singh R; Higashitani F; Kunugita C; Nishida K; Uji T. 2-Oxo-1-azetidine sulfonic acid derivatives as potent b-lactamase inhibitors. International Patent, WO98/47895; October 29, 1998. 

  7. Dimmock JR; Phillips OA; Hickie RA. Aminostyryl ketones. Canadian Patent 1339743, March 17, 1998. 

  8. Maiti SN; Phillips OA; Reddy AVN; Setti EL; Micetich RG; Kunugita C; Higashitani F; Hyodo A. Novel penam sulfones as b-lactamase inhibitors. International Patent, WO 97/06172; February 20, 1997. 

  9. Maiti SN; Phillips OA; Reddy AVN; Setti EL; Micetich RG; Kunugita C; Higashitani F; Hyodo A. Penam sulfones as b-lactamase inhibitors. United States Patent, US 5686441; November 11, 1997.

     

Abstracts published in journals:

Almufarreh SA, Udo EE, Novotny L, Paulikova H, Kozurkova M, Phillips OA (2018). Antibacterial and antiproliferative activity of novel triazolyl-oxazolidinones. Med Princ Pract – Published Online: January 17, 2018. (Abstracts of award-winning Posters - 22nd Annual Health Sciences Poster Conference, Faculty of Medicine, Health Sciences Centre, Kuwait University, Kuwait, March 7-9, 2017).

Kehinde EO, Abdel-Hamid M, Philips OA, Sharaf L, Babu A (2010). A comparative pharmacokinetic study of seven brands of ciprofloxacin in NZW rabbits using liquid chromatography mass spectrometry technique. J. Urol. 183(4)(suppl):e316-e317.